These results support a Phase II trial to evaluate Treg therapy (78), and insulin-specific CAR-Tregs remain a promising avenue for immunomodulation in T1D (79), potentially enhanced by combining mAb287 CAR-T cells with specific CAR-Tregs. This evidence concerns the gene INS and type 1 diabetes mellitus.